Glucagon-like peptide 1--a cardiologic dimension

Trends Cardiovasc Med. 2010 Jan;20(1):8-12. doi: 10.1016/j.tcm.2010.02.012.

Abstract

Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Cardiovascular Agents / therapeutic use*
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucagon-Like Peptide 1 / metabolism
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Heart Diseases / drug therapy*
  • Heart Diseases / metabolism
  • Heart Diseases / physiopathology
  • Humans
  • Myocardial Contraction / drug effects
  • Myocardial Reperfusion Injury / prevention & control
  • Signal Transduction / drug effects
  • Treatment Outcome
  • Vasodilation / drug effects
  • Ventricular Function, Left / drug effects

Substances

  • Cardiovascular Agents
  • Glucagon-Like Peptide 1